Neuroprotective role of Z-ligustilide against forebrain ischemic injury in ICR mice.
Radix Angelica sinensis, known as Danggui in Chinese, has been used to treat cardiovascular and cerebrovascular diseases in Traditional Chinese Medicine for a long time. Modern phytochemical studies showed that Z-ligustilide (LIG) is the main lipophilic component of Danggui. In this study, we examined whether LIG could protect ischemia/reperfusion-induced brain injury by minimizing oxidative stress and anti-apoptosis. Transient forebrain cerebral ischemia (FCI) was induced by the bilateral common carotid arteries occlusion for 30 min. LIG was intraperitoneally injected to ICR mice at the beginning of reperfusion. As determined via 2,3,5-triphenyl tetrazolium chloride (TTC) staining at 24 h following ischemia, the infarction volume in the FCI mice treated without LIG (22.1 +/- 2.6%) was significantly higher than that in the FCI mice treated with 5 mg/kg (11.8 +/- 5.2%) and 20 mg/kg (2.60 +/- 1.5%) LIG (P < 0.05 or P < 0.01). LIG treatment significantly decreased the level of malondialdehyde (MDA) and increased the activities of the antioxidant enzyme glutathione peroxidase (GSH-PX) and superoxide dismutase (SOD) in the ischemic brain tissues (P < 0.05 or P < 0.01 vs. FCI group). In addition, LIG provided a great increase in Bcl-2 expression as well as a significant decrease in Bax and caspase-3 immunoreactivities in the ischemic cortex. The findings demonstrated that LIG could significantly protect the brain from damage induced by transient forebrain cerebral ischemia. The antioxidant and anti-apoptotic properties of LIG may contribute to the neuroprotective potential of LIG in cerebral ischemic damage.
Kuang
X
X
Department of Pharmacology, Sichuan University College of Pharmacy, Chengdu, P R China.
Yao
Y
Y
Du
J R
JR
Liu
Y X
YX
Wang
C Y
CY
Qian
Z M
ZM
D015107:4-Butyrolactone / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use; D000704:Analysis of Variance; D000818:Animals; D020520:Brain Infarction / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005979:Glutathione Peroxidase / Q000378:metabolism; D007150:Immunohistochemistry / Q000379:methods; D002546:Ischemic Attack, Transient / Q000188:drug therapy* / Q000473:pathology*; D008315:Malondialdehyde / Q000378:metabolism; D051379:Mice; D008813:Mice, Inbred ICR; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D016548:Prosencephalon / Q000187:drug effects*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D015424:Reperfusion / Q000379:methods; D013482:Superoxide Dismutase / Q000378:metabolism; D013778:Tetrazolium Salts / Q000737:chemistry; D051028:bcl-2-Associated X Protein / Q000378:metabolism
D018696:Neuroprotective Agents; D019253:Proto-Oncogene Proteins c-bcl-2; D013778:Tetrazolium Salts; D051028:bcl-2-Associated X Protein; C027820:ligustilide; D008315:Malondialdehyde; C009591:triphenyltetrazolium; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; C505409:Casp3 protein, mouse; D053148:Caspase 3; D020169:Caspases; D015107:4-Butyrolactone